BC Week In Review | Jan 18, 2019
Financial News

Kaleido, Cirius seeking NASDAQ listings

Kaleido Biosciences Inc. (Lexington, Mass.) and Cirius Therapeutics Inc (San Diego, Calif.) each proposed NASDAQ IPOs on Jan 11. Kaleido, which is designing therapies to modulate the metabolic output and profile of the microbiome, is...
BC Extra | Jan 12, 2019
Financial News

Kaleido, Cirius seeking NASDAQ listings

Kaleido Biosciences Inc. (Lexington, Mass.) and Cirius Therapeutics Inc (San Diego, Calif.) each proposed NASDAQ IPOs on Friday. Kaleido, which is designing therapies to modulate the metabolic output and profile of the microbiome, is seeking...
BioCentury | Mar 16, 2018
Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co....
BC Innovations | Nov 30, 2017
Translation in Brief

Two faces of FOXO1

Columbia University and AstraZeneca plc (LSE:AZN; NYSE:AZN) have identified the first FOXO1 inhibitors that can selectively block the transcription factor’s glucose-stimulating activity without inducing lipogenesis. Optimization of the compounds could yield a therapy for Type...
BioCentury | Apr 14, 2017
Finance

More NASH cash

Investors are hoping a $40 million A-2 round can help Cirius Therapeutics Inc. deliver the first clinical data in non-alcoholic steatohepatitis (NASH) showing a second-generation insulin sensitizer is not only efficacious, but also avoids the...
BC Innovations | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
BC Week In Review | Oct 14, 2013
Clinical News

Metabolic Solutions preclinical data

In a mouse model of PD, MSDC-0160 improved motor deficits, restored neurotransmitter levels in the striatum and protected dopaminergic neurons in the substantia nigra. Data were presented at the Grand Challenges in Parkinson's Disease meeting...
BC Week In Review | Sep 23, 2013
Clinical News

Mitoglitazone: Phase IIa data

A double-blind, U.S. Phase IIa trial in 29 non-diabetic patients aged 55-85 with mild AD showed that once-daily 150 mg MSDC-0160 met the primary endpoint of improving regional glucose metabolism levels in regions of the...
BC Week In Review | Jun 18, 2012
Clinical News

Mitoglitazone: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 266 Type II diabetics showed that once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing FPG from baseline to week 12...
BC Extra | Jun 12, 2012
Clinical News

Metabolic Solutions' TZD analog meets Phase IIb diabetes endpoint

Metabolic Solutions Development Co. (Kalamazoo, Mich.) said once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing fasting plasma glucose from baseline to week 12 vs. placebo in a Phase IIb trial...
Items per page:
1 - 10 of 20
BC Week In Review | Jan 18, 2019
Financial News

Kaleido, Cirius seeking NASDAQ listings

Kaleido Biosciences Inc. (Lexington, Mass.) and Cirius Therapeutics Inc (San Diego, Calif.) each proposed NASDAQ IPOs on Jan 11. Kaleido, which is designing therapies to modulate the metabolic output and profile of the microbiome, is...
BC Extra | Jan 12, 2019
Financial News

Kaleido, Cirius seeking NASDAQ listings

Kaleido Biosciences Inc. (Lexington, Mass.) and Cirius Therapeutics Inc (San Diego, Calif.) each proposed NASDAQ IPOs on Friday. Kaleido, which is designing therapies to modulate the metabolic output and profile of the microbiome, is seeking...
BioCentury | Mar 16, 2018
Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co....
BC Innovations | Nov 30, 2017
Translation in Brief

Two faces of FOXO1

Columbia University and AstraZeneca plc (LSE:AZN; NYSE:AZN) have identified the first FOXO1 inhibitors that can selectively block the transcription factor’s glucose-stimulating activity without inducing lipogenesis. Optimization of the compounds could yield a therapy for Type...
BioCentury | Apr 14, 2017
Finance

More NASH cash

Investors are hoping a $40 million A-2 round can help Cirius Therapeutics Inc. deliver the first clinical data in non-alcoholic steatohepatitis (NASH) showing a second-generation insulin sensitizer is not only efficacious, but also avoids the...
BC Innovations | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
BC Week In Review | Oct 14, 2013
Clinical News

Metabolic Solutions preclinical data

In a mouse model of PD, MSDC-0160 improved motor deficits, restored neurotransmitter levels in the striatum and protected dopaminergic neurons in the substantia nigra. Data were presented at the Grand Challenges in Parkinson's Disease meeting...
BC Week In Review | Sep 23, 2013
Clinical News

Mitoglitazone: Phase IIa data

A double-blind, U.S. Phase IIa trial in 29 non-diabetic patients aged 55-85 with mild AD showed that once-daily 150 mg MSDC-0160 met the primary endpoint of improving regional glucose metabolism levels in regions of the...
BC Week In Review | Jun 18, 2012
Clinical News

Mitoglitazone: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 266 Type II diabetics showed that once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing FPG from baseline to week 12...
BC Extra | Jun 12, 2012
Clinical News

Metabolic Solutions' TZD analog meets Phase IIb diabetes endpoint

Metabolic Solutions Development Co. (Kalamazoo, Mich.) said once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing fasting plasma glucose from baseline to week 12 vs. placebo in a Phase IIb trial...
Items per page:
1 - 10 of 20